Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes

Drug Metabolism and Disposition

Volumn 33, Issue 4, 2005, Pages 500-507

  Zhu, Mingshe ^a   Zhao, Weiping ^a   Jimenez, Humberto ^a   Zhang, Donglu ^a   Yeola, Suresh ^a   Dai, Renke ^a   Vachharajani, Nimish ^a   Mitroka, James ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 PYRIMIDINYLPIPERAZINE; 5 HYDROXYBUSPIRONE; 6' HYDROXYBUSPIRONE; BUSPIRONE; BUSPIRONE N OXIDE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEALKYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME MECHANISM; GENOTYPE; HUMAN; HUMAN TISSUE; HYDROXYLATION; LIVER MICROSOME; OXIDATION; PRIORITY JOURNAL;

ANIMALS; ANTI-ANXIETY AGENTS; ARYL HYDROCARBON HYDROXYLASES; BUSPIRONE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; HUMANS; INSECTS; ISOENZYMES; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; RECOMBINANT PROTEINS;

EID: 15344344076     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.000836     Document Type: Article

References (30)

1. Apter JT and Allen LA (1999) Buspirone: future directions. J Clin Psychopharmacol 19:86-93.
2. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King P, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832.
3. Caccia S, Muglia M, Mancinelli A, and Garattini S (1983) Disposition and metabolism of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in the rat. Xenobiotica 13:147-153.
4. [FDA/CDER]Food and Drug Administration/Center for Drug Evaluation and Research (1999) Guidance for industry: in vivo drug metabolism/drug interaction studies: study design, data analysis and recommendations for dosing and labeling, http://www.fda.gov/cder/guidance/2635fnl.htm, Oct 6, 1999. Center for Drug Evaluation and Research, Rockville, MD.
5. Fulton B and Brogden RN (1997) Buspirone: an updated review of its clinical pharmacology and therapeutic applications. CNS Drugs 7:68-88.
6. Gammans RE, Mayol RF, and LaBudder JA (1986) Metabolism and disposition of buspirone. Am J Med 80 (Suppl 3B):41-51.
7. Gammans RE, Mayol RF, Mackenthum AV, and Sokya LF (1985) The relationship between buspirone bioavailability and dose in healthy subjects. Biopharm Drug Dispos 6:139-145.
8. Goa KL and Ward A (1986) Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 32:114-129.
9. Goldthwaite CA Jr, Hsieh FY, Womble SW, Nobes BJ, Blair IA, Klunk LJ, and Mayol RF (1996) Liquid chromatography/chemical reaction interface mass spectrometry as an alternative to radioisotopes for quantitative drug metabolism studies. Anal Chem 68:2996-3001.
10. Greenblatt DJ, von Moltke LL, Giancarlo GM, and Garteiz DA (2003) Human cytochromes mediating gepirone biotransformation at low substrate concentrations. Biopharm Drug Dispos 24:87-94.
11. Jajoo HK, Blair IA, Klunk LJ, and Mayol RF (1990) In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo. Xenobiotica 20:779-786.
12. Jajoo HK, Mayol RF, LaBudder JA, and Blair IA (1989a) Metabolism of the antianxiety drug buspirone in the rat. Drug Metab Dispos 17:625-633.
13. Jajoo HK, Mayol RF, LaBudder JA, and Blair IA (1989b) Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos 17:634-640.
14. Kerns EH, Rourick RA, Volk KJ, and Lee MS (1997) Buspirone metabolite structure profile using a standard liquid chromatographic-mass spectrometric protocol. J Chromatogr Biomed Appl 698:133-145.
15. Kivisto KT, Lamberg TS, Kantola T, and Neuvonen PJ (1997) Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 62:348-354.
16. Kivisto KT, Lamberg TS, and Neuvonen PJ (1999) Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone. Pharmacol Toxicol 84:94-97.
17. Laine K, Ahokoski O, Huupponen R, Hanninen J, Palovaara S, Ruuskanen J, Bjorklund H, Anttila M, and Rouru J (2003) Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone. Eur J Pharmacol 59:761-766.
18. Lamberg TS, Kivisto KT, and Neuvonen PJ (1998a) Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin Pharmacol Ther 63:640-645.
19. Lamberg TS, Kivisto KT, and Neuvonen PJ (1998b) Concentrations and effects of buspirone are considerably reduced by rifampicin. Br J Clin Pharmacol 45:381-405.
20. Lilja JJ, Kivisto KT, Backman JT, Lamberg TS, and Neuvonen PJ (1998) Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 64:655-660.
21. Mahmood I and Sahajwalla C (1999) Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet 36:277-287.
22. 14C-buspirone HCI after intravenous and oral dosing in man. Clin Pharmacol Ther 37:210.
23. O'Hanlon JF (1991) Review of buspirone's effect on human performance and related variables. Eur Neuropsychopharmacol 1:489-501.
24. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping. Biochem Pharmacol 57:465-480.
25. Sramek JJ, Zarotsky V, and Cutler NR (2002) Generalised anxiety disorder treatment options. Drugs 62:1635-1648.
26. Suzuki H, Kneller MB, Haining RL, Trager WF, and Rettie AE (2002) (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. Drug Metab Dispos 30:235-239.
27. Tucker GT, Houston JB, and Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm Res (NY) 18:1071-1080.
28. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Fogelman SM, Harmatz JS, Kramer SJ, Fabre LF, and Shader RI (1998) Gepirone and 1-(2-pyrimidinyl)- piperazine in vitro: human cytochromes mediateding transformation and cytochrome inhibitory effects. Psychopharmacology 140:293-299.
29. Zhu M, Bering N, and Mitroka J (2000) Use of HPLC with 96-well microplate scintillation counter for rapid profiling of low levels of radioactive metabolites in biological fluids. Drug Metab Rev 32 (Suppl 2):177.
30. Zhu M, Zhang H, Zhao W, Mitroka J, and Klunk L (2002) A novel in vitro approach, using a microplate scintillation counter and LC/MS for determining formation pathways and structures of sequential metabolites: buspirone as an example. Drug Metab Rev 34 (Suppl 1):167.